Radioembolization in the Treatment of Neuroendocrine Tumors
Journal Title: Nükleer Tıp Seminerleri - Year 2019, Vol 5, Issue 2
Abstract
Presence of liver metastases in a neuroendocrine tumor (NET) patient determines survival. Although surgical resection is accepted as a curative treatment modality, the multifocal and disseminated nature of hepatic metastases in NET patients does not allow this modality to be used often. There is no consensus for the convenient choice of treatment for inoperable hepatic metastases in NET patients. In this review, usage of radioembolization in NET patients with hepatic metastases is discussed along with other local and systemic therapy modalities.
Authors and Affiliations
Zeynep Gözde Özkan
Keywords
Related Articles
- EP ID EP604006
- DOI 10.4274/nts.galenos.2019.0020
- Views 113
- Downloads 0
Dosimetry in Nuclear and Radiation Emergencies
Radiation absorbed dose assessment has critical importance especially in mass casualty conditions for sorting (triage) and medical management of patients in nuclear or radiological emergencies. Dose estimates can be done...
Sentinel Lymph Node Imaging and Biopsy in Breast Cancer
The histological status of axillary lymph nodes is an important prognostic factor in patients receiving surgery for breast cancer. Sentinel lymph node biopsy provides staging information to guide adjuvant therapy and pot...
Radioembolization: Personalized Treatment and Protection from Side Effects
Y-90 microsphere therapy fits very well to the principal of medical practice “primum non nocere”. Owing to its unique theoritical basis, Y-90 microsphere treatment may show a much higher therapeutic efficacy along with m...
Orthopedic Models and Imaging Techniques in Preclinical Researchs
Tendinopathies and osteoarthritis developed after cartilage damage are chronic health problems that decrease the patient’s quality of life. Osteoporosis is another important health problem leading to fractures. In the tr...
Lu-177 Prostate Specific Membrane Antigen Therapy of Metastatic Castration Resistant Prostate Cancer
Lu-177 prostate-specific membrane antigen (PSMA) has been increasingly used for treatment of metastatic castration-resistant prostate cancer. It is effective in pain palliation for bone metastasis and improves patient pe...